Elanco Animal Health

Fitch Ratings has raised Elanco’s long-term issuer default rating from BB to BB+ and upgraded the rating on senior secured obligations to BBB-, with a stable outlook. The agency cites successful debt reductions of about $650 million since 2024, market share gains in the pet health segment, a broad product portfolio and improved cash‑flow generation. Fitch expects leverage to fall (gross leverage toward 3.0x by end‑2027), rising free cash flows through 2028 and EBITDA margins of around 21–22% after 2026. In the near term, freed cash flow is expected to be used primarily for debt repayment, while Elanco invests in product expansion, manufacturing and targeted acquisitions. » More on de.investing.com

Elanco has received emergency approval from the FDA for the wound spray CLiK Extra, authorized to prevent infestations by the New World screw-worm fly in livestock and certain wild animals. The topical dicyclanil suspension may be used on sheep, cattle, goats, swine, camelids, captive deer, American bison, bighorn sheep and pronghorn, but it does not treat active infestations. Animals of the listed species must not be slaughtered for human consumption within 86 days after treatment; there is no established milk withdrawal period, and the product must not be used on milk-producing animals for human consumption. CLiK Extra will be available through usual veterinary distribution channels and the approval is valid for the duration of the federal emergency. » More on de.investing.com

Data in Parasites & Vectors show that Credelio Quattro reduces infections with black-legged ticks within 8 hours after treatment, both on day 0 and on day 28 of the dosing interval. Competing products Simparica Trio and NexGard Plus achieved significant reductions only after 12 and 24 hours, respectively, on day 28. Credelio Quattro is FDA-approved for Lyme prevention in dogs; common side effects in studies were vomiting and diarrhea, and the drug class has been linked to neurological effects. » More on de.investing.com